Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

ISR Stock: Why Little-Known Isoray Is Surging 200% Today

By Robert Lakin, InvestorPlace Contributor

An FDA nod on Isoray's prostate treatment using brachytherapy seeds sent ISR stock skyrocketing. There's risk with uncertain reward in this biopharma stock.

ALRN Stock: What Investors Should Know About Aileron Therapeutics

By Robert Lakin, InvestorPlace Contributor

As with many biopharma names, there's volatility and risk in ALRN stock. This firm is seeking to reduce the effects of chemotherapy.

ZSAN Stock: What Investors Should Know About Zosano Pharma

By Robert Lakin, InvestorPlace Contributor

News that migraine-treatment maker Zosano Pharma will reapproach the FDA for approval has ZSAN stock jumping this morning. Investors should be cautious as penny stocks can cause big headaches.

ZOM Stock: Why Pet Care Play Zomedica Is on the Move

By Robert Lakin, InvestorPlace Contributor

Zomedica Pharmaceuticals is riding the wave of rising pet care spending. What's got tails wagging this morning about ZOM stock?

OCGN Stock: Why Ocugen Shares Are Soaring 70% Today

By Robert Lakin, InvestorPlace Contributor

Ocugen shares surged after its Indian development partner got emergency-use authorization for its Covid-19 vaccine. OCGN stock remains one to watch as new virus waves strike.

Load More